Authors:

Andrei Iagaru MD
Professor of Radiology - Nuclear Medicine
Chief of the Division of Nuclear Medicine and Molecular Imaging
Stanford University Medical Center

Steven Rowe MD PhD
Associate Professor of Radiology and Radiological Science
Johns Hopkins University

Target Audience

This 90-minute (approximately) course contains information of value to physicians in nuclear medicine radiology oncology and urology using 18F-DCFPyL (PYLARIFY®)  an FDA-approved radioactive diagnostic agent for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.   This course is intended for physicians  nuclear medicine technologists and any professionals in nuclear medicine and related fields. 

For optimal viewing please download the PDF content file and open it using Adobe vs. viewing it in a browser.

Content updated 7/11/2023.

Objectives

At the completion of this activity the participant will be able to:

1. Describe the mechanism of action of 18F-DCFPyL 
2. Identify the normal biodistribution of the 18F-DCFPyL cases
3. Understand the expected physiologic uptake patterns incidental findings and normal variants
4. Interpret 18F-DCFPyL scans

Continuing Education Credit Information

This course does not offer continuing education credits.  Upon successful completion of the assessment participants will receive a certificate of training.